Efficacy of SCH 39304 in treatment of experimental invasive aspergillosis

The efficacy of SCH 39304 (SCH) against Aspergillus fumigatus was assessed with an immunosuppressed, temporarily leukopenic rabbit model of invasive aspergillosis. Therapy with SCH at 10 or 15 mg/kg of body weight per day was begun 24 h after lethal challenge and compared with therapy with amphotericin B at 1.5 mg/kg/day. Compared with untreated controls, SCH reduced mortality and also reduced the tissue burden of A. fumigatus 100- to 1,000-fold in liver, kidney, and lung tissues. SCH at 15 mg/kg/day and amphotericin B eliminated A. fumigatus in liver, kidney, and lung tissues. In addition, both dosages of SCH significantly eliminated the organism from brain tissues, compared with controls. Both SCH and amphotericin B decreased or eliminated circulating aspergillus antigen. These results show that new azoles can be as effective as amphotericin B in eradicating the organism from tissues and offer promise in improving the treatment of invasive aspergillosis.

[1]  J. Lesher.  NEW ANTIFUNGAL AGENTS , 1992, Dermatologic clinics.

[2]  T. Patterson,et al.  The role of fluconazole in the early treatment and prophylaxis of experimental invasive aspergillosis. , 1991, The Journal of infectious diseases.

[3]  J. Graybill,et al.  Pulmonary aspergillosis in mice: treatment with a new triazole SCH39304. , 1990, The American review of respiratory disease.

[4]  D. Loebenberg,et al.  Pharmacokinetics and tissue penetration of Sch 39304 in granulocytopenic and nongranulocytopenic rabbits , 1989, Antimicrobial Agents and Chemotherapy.

[5]  F. Szoka,et al.  Treatment of experimental invasive aspergillosis with novel amphotericin B/cholesterol-sulfate complexes. , 1989, The Journal of infectious diseases.

[6]  J. Ryan,et al.  Effect of immunosuppression and amphotericin B on Aspergillus antigenemia in an experimental model. , 1988, The Journal of infectious diseases.

[7]  R. Fromtling.  Overview of medically important antifungal azole derivatives , 1988, Clinical Microbiology Reviews.

[8]  V. Andriole,et al.  The diagnosis of invasive aspergillosis by an enzyme-linked immunosorbent assay for circulating antigen. , 1985, The Journal of infectious diseases.

[9]  J. Graybill,et al.  Experimental murine aspergillosis. Comparison of amphotericin B and a new polyene antifungal drug, SCH 28191. , 1984, The American review of respiratory disease.

[10]  J. Aisner,et al.  Treatment of invasive aspergillosis: relation of early diagnosis and treatment to response. , 1977, Annals of internal medicine.

[11]  V. Devita,et al.  Aspergillosis. The spectrum of the disease in 98 patients. , 1970, Medicine.